Abstract
Keywords
Introduction
World Health Organisation, 2021, Available at: https://www.who.int/news-room/fact-sheets/detail/cancer . Accessed November 2021.
Cancer Research UK, Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero. Accessed November 2021.
National Institute for Health Research NIHR funding and awards search website (2020). Available at: https://fundingawards.nihr.ac.uk/award/NIHR131120. Accessed March, 2022
Material and Methods
Sample and volumes
Patient no. | Laterality | Primary site | Nodal targets | Prescription | CT | PTVp_4000 volume (cc) | PTVn_LN_Combined volume (cc) |
---|---|---|---|---|---|---|---|
1 | Left | CW | Level 2-4, IP, IMN | 40 Gy/15 | DIBH | 286.93 | 122.21 |
2 | Left | CW | Level 2-4, IMN | 40 Gy/15 | DIBH | 748.57 | 127.33 |
3 | Right | CW | Level 2-4, IP, IMN | 40 Gy/15 | DIBH | 583.93 | 168.23 |
4 | Left | CW | Level 2-4, IP, IMN | 40 Gy/15 | DIBH | 476.91 | 141.84 |
5 | Right | CW | Level 3-4, IMN | 40 Gy/15 | DIBH | 427.28 | 121.39 |
6 | Left | WB | Level 2-4, IMN | 40 Gy/15 | DIBH | 966.37 | 137.09 |
7 | Right | CW | Level 2-4, IP, IMN | 40 Gy/15 | DIBH | 229.3 | 102.26 |
8 | Left | CW | Level 2-4, IP, IMN | 40 Gy/15 | DIBH | 860.23 | 178.85 |
9 | Right | CW | Level 3-4, IMN | 40 Gy/15 | DIBH | 313.34 | 224.88 |
10 | Right | CW | Level 2-4, IP, IMN | 40Gy/15 | DIBH | 1345.45 | 144.21 |
Organ | Target/OAR | Objective | Mandatory |
---|---|---|---|
PTVp | Target | V38 Gy > 95% | V36 Gy > 90% |
V42.8 Gy ≤ 2% | D0.5cc ≤ 44Gy | ||
PTVn_IMN, PTVn_LN | Target | V36 Gy > 90% | V32 Gy > 80% |
V42.8 Gy ≤ 2% | D0.5cc ≤ 44Gy | ||
Body-PTVs & fields | OAR | V42.8 Gy ≤ 2cc | D0.5cc ≤ 44 Gy |
Ipsi_Lung | OAR | Mean < 13 Gy | V17 Gy < 35% |
Contra_ Lung | OAR | V2.5 Gy < 3% | N/A |
Mean < 1Gy | |||
Heart (left-sided tumor) | OAR | V13 Gy < 2% | V13 Gy < 10% |
Mean < 3Gy | Mean < 4 Gy | ||
Heart (right-sided tumor) | OAR | V5 Gy < 6% | V13 Gy < 10% |
Mean < 1.7 Gy | Mean < 4 Gy | ||
Contra_Breast | OAR | Mean < 3.5 Gy | N/A |
Isocenter shifted 5 mm | Flash simulation scenario | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROI | Technique | Plan | Medial | Lateral | Posterior | Anterior | Inferior | Superior | SOM1 | SOM2 | SOM3 | SOM4 | SOM5 | CBCT |
CTVp | ||||||||||||||
V38 Gy (%) | WT | 99.5 ± 0.3 | 99.1 ± 0.9 | 99.2 ± 0.5 | 98.3 ± 1.8 | 99.0 ± 0.5 | 99.2 ± 0.7 | 99.1 ± 0.9 | 91.6 ± 7.7 | 79.5 ± 13.7 | 97.9 ± 1.5 | 95.3 ± 4.2 | 77.7 ± 16.5 | 97.5 ± 2.1 |
VMAT NF | 99.4 ± 0.4 | 95.3 ± 2.3 | 99.6 ± 0.3 | 91.0 ± 3.8 | 99.3 ± 0.6 | 99.1 ± 0.6 | 99.1 ± 0.6 | 64.4 ± 11.6 | 49.0 ± 18.9 | 90.1 ± 4.6 | 81.5 ± 7.8 | 36.3 ± 17.3 | 96.1 ± 3.5 | |
VMAT MF | 99.8 ± 0.3 | 98.9 ± 1.3 | 99.7 ± 0.3 | 98.6 ± 1.7 | 99.5 ± 0.5 | 99.7 ± 0.3 | 99.4 ± 0.9 | 89.3 ± 8.6 | 84.1 ± 8.2 | 97.4 ± 2.8 | 96.0 ± 3.8 | 76.5 ± 11.8 | 98.0 ± 3.0 | |
VMAT RO | 99.9 ± 0.1 | 99.8 ± 0.1 | 99.4 ± 0.4 | 99.9 ± 0.1 | 98.8 ± 0.9 | 99.8 ± 0.1 | 99.7 ± 0.1 | 95.5 ± 3.0 | 94.2 ± 4.2 | 99.5 ± 0.3 | 99.4 ± 0.3 | 88.0 ± 6.0 | 97.9 ± 3.2 | |
D0.5cc (Gy) | WT | 43.2 ± 0.5 | 43.4 ± 0.6 | 43.2 ± 0.5 | 43.5 ± 0.6 | 43.3 ± 0.5 | 43.5 ± 0.5 | 43.1 ± 0.4 | 42.9 ± 0.9 | 42.2 ± 1.1 | 43.0 ± 0.6 | 42.8 ± 0.7 | 42.1 ± 1.1 | 43.0 ± 0.6 |
VMAT NF | 42.4 ± 0.6 | 42.2 ± 0.6 | 42.7 ± 0.6 | 42.5 ± 0.8 | 42.8 ± 0.6 | 42.4 ± 0.6 | 42.4 ± 0.6 | 41.8 ± 0.9 | 41.4 ± 1.2 | 42.1 ± 0.6 | 41.9 ± 0.9 | 41.1 ± 0.9 | 42.1 ± 0.7 | |
VMAT MF | 42.6 ± 0.3 | 42.6 ± 0.3 | 42.9 ± 0.5 | 43.0 ± 0.5 | 42.9 ± 0.6 | 42.7 ± 0.4 | 42.7 ± 0.4 | 43.1 ± 1.0 | 43.2 ± 0.9 | 42.8 ± 0.5 | 42.8 ± 0.5 | 42.9 ± 1.0 | 42.5 ± 0.5 | |
VMAT RO | 42.8 ± 0.5 | 42.3 ± 0.6 | 42.5 ± 0.5 | 42.6 ± 0.5 | 42.6 ± 0.5 | 42.3 ± 0.5 | 42.3 ± 0.4 | 42.5 ± 0.7 | 42.5 ± 0.6 | 42.3 ± 0.7 | 42.3 ± 0.5 | 41.8 ± 0.4 | 42.2 ± 0.6 | |
CTVp_SP | ||||||||||||||
V38 Gy (%) | WT | 98.9 ± 1.3 | 98.2 ± 1.4 | 98.5 ± 1.9 | 97.1 ± 2.1 | 98.3 ± 2.3 | 98.4 ± 2.0 | 98.8 ± 1.2 | 87.4 ± 10.1 | 79.0 ± 16.6 | 95.0 ± 3.7 | 91.8 ± 5.7 | 73.3 ± 21.9 | 95.5 ± 3.9 |
VMAT NF | 98.0 ± 1.7 | 87.0 ± 6.0 | 98.9 ± 1.3 | 75.6 ± 9.5 | 98.6 ± 1.6 | 97.0 ± 3.5 | 97.4 ± 2.0 | 35.8 ± 13.6 | 39.3 ± 18.6 | 73.0 ± 11.4 | 56.0 ± 14.5 | 27.8 ± 14.0 | 90.3 ± 7.8 | |
VMAT MF | 99.3 ± 0.8 | 97.2 ± 2.6 | 99.2 ± 1.0 | 96.6 ± 2.7 | 98.9 ± 1.2 | 98.8 ± 1.5 | 99.1 ± 1.1 | 80.0 ± 10.4 | 76.9 ± 12.8 | 93.6 ± 4.8 | 91.3 ± 5.4 | 69.2 ± 15.2 | 95.6 ± 5.3 | |
VMAT RO | 99.6 ± 0.5 | 99.5 ± 0.6 | 99.0 ± 0.9 | 99.5 ± 0.6 | 98.2 ± 1.0 | 99.4 ± 0.8 | 99.5 ± 0.7 | 91.2 ± 5.5 | 92.2 ± 6.6 | 98.4 ± 1.4 | 98.2 ± 1.7 | 86.4 ± 7.7 | 96.7 ± 4.0 | |
CTVn_IMN | ||||||||||||||
V36 Gy (%) | WT | 86.9 ± 13.1 | 89.7 ± 10.7 | 79.2 ± 16.4 | 91.1 ± 9.8 | 74.0 ± 16.3 | 91.7 ± 8.9 | 78.1 ± 16.1 | 84.7 ± 15.7 | 82.9 ± 18.3 | 88.7 ± 11.1 | 88.6 ± 9.8 | 82.3 ± 20.7 | 83.1 ± 19.0 |
VMAT NF | 100 ± 0.0 | 99.9 ± 0.02 | 99.9 ± 0.02 | 100 ± 0.0 | 99.8 ± 0.2 | 100 ± 0.0 | 99.8 ± 0.1 | 100 ± 0.0 | 99.8 ± 0.6 | 100 ± 0.0 | 99.9 ± 0.06 | 99.7 ± 0.8 | 99.8 ± 0.3 | |
VMAT MF | 100 ± 0.0 | 100 ± 0.0 | 99.9 ± 0.08 | 100 ± 0.0 | 99.8 ± 0.2 | 100 ± 0.0 | 99.8 ± 0.1 | 100 ± 0.0 | 99.9 ± 0.01 | 100 ± 0.0 | 99.9 ± 0.003 | 99.9 ± 0.07 | 99.8 ± 0.3 | |
VMAT RO | 100 ± 0.0 | 100 ± 0.0 | 99.8 ± 0.1 | 100 ± 0.0 | 99.1 ± 0.8 | 99.9 ± 0.2 | 99.6 ± 0.2 | 100 ± 0.0 | 99.9 ± 0.03 | 100 ± 0.0 | 99.9 ± 0.01 | 99.9 ± 0.01 | 99.9 ± 0.2 | |
D0.5cc (Gy) | WT | 41.3 ± 1.0 | 41.5 ± 0.9 | 40.8 ± 1.1 | 41.9 ± 1.0 | 40.6 ± 1.0 | 41.6 ± 0.9 | 40.8 ± 1.0 | 41.3 ± 1.0 | 41.0 ± 1.0 | 41.3 ± 1.0 | 41.4 ± 0.6 | 41.0 ± 1.1 | 41.1 ± 1.1 |
VMAT NF | 41.6 ± 0.4 | 41.3 ± 0.4 | 41.8 ± 0.5 | 41.1 ± 0.6 | 42.3 ± 0.7 | 41.5 ± 0.4 | 41.7 ± 0.3 | 40.6 ± 0.4 | 40.8 ± 0.7 | 41.0 ± 0.4 | 41.2 ± 0.5 | 40.4 ± 0.6 | 41.4 ± 0..7 | |
VMAT MF | 41.5 ± 0.4 | 41.2 ± 0.4 | 41.7 ± 0.5 | 41.1 ± 0.7 | 42.2 ± 0.7 | 41.5 ± 0.5 | 41.6 ± 0.4 | 40.5 ± 0.5 | 40.8 ± 0.8 | 40.9 ± 0.4 | 41.1 ± 0.6 | 40.4 ± 0.7 | 41.3 ± 0.7 | |
VMAT RO | 40.9 ± 0.5 | 40.9 ± 0.4 | 41.0 ± 0.7 | 40.9 ± 0.4 | 41.1 ± 0.8 | 41.0 ± 0.4 | 40.8 ± 0.7 | 40.3 ± 0.6 | 40.3 ± 0.7 | 40.5 ± 0.5 | 40.7 ± 0.5 | 40.2 ± 0.7 | 40.8 ± 0.8 | |
CTVn_LN | ||||||||||||||
V36 Gy (%) | WT | 94.2 ± 5.1 | 94.1 ± 5.0 | 92.3 ± 6.4 | 95.5 ± 4.2 | 91.5 ± 6.3 | 94.4 ± 5.5 | 92.2 ± 6.5 | 93.6 ± 6.0 | 92.1 ± 7.3 | 94.2 ± 5.2 | 94.1 ± 5.0 | 92.3 ± 7.9 | 93.4 ± 7.5 |
VMAT NF | 100 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 100 ± 0.0 | 99.9 ± 0.2 | 100 ± 0.0 | 100 ± 0.0 | 99.6 ± 0.6 | 99.9± 0.1 | |
VMAT MF | 100 ± 0.0 | 100 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 100 ± 0.0 | 100 ± 0.0 | 99.7 ± 0.4 | 99.9 ± 0.1 | |
VMAT RO | 100 ± 0.0 | 100 ± 0.0 | 99.9 ± 0.0 | 99.9 ± 0.0 | 99.8 ± 0.1 | 99.9 ± 0.0 | 99.9 ± 0.0 | 100 ± 0.0 | 100 ± 0.0 | 100 ± 0.0 | 99.9 ± 0.0 | 99.8 ± 0.2 | 99.9 ± 0.0 | |
D0.5cc (Gy) | WT | 42.7 ± 0.5 | 42.7 ± 0.4 | 42.6 ± 0.3 | 43.2 ± 0.4 | 42.2 ± 0.4 | 42.7 ± 0.4 | 42.6 ± 0.4 | 42.7 ± 0.4 | 42.8 ± 0.4 | 42.7 ± 0.4 | 42.7 ± 0.4 | 42.8 ± 0.4 | 42.8 ± 0.4 |
VMAT NF | 41.7 ± 0.3 | 41.4 ± 0.3 | 41.9 ± 0.4 | 41.2 ± 0.5 | 42.5 ± 0.6 | 41.6 ± 0.4 | 41.8 ± 0.2 | 41.1 ± 0.3 | 41.3 ± 0.4 | 41.3 ± 0.3 | 41.5 ± 0.3 | 41.1 ± 0.4 | 41.7 ± 0.7 | |
VMAT MF | 41.6 ± 0.4 | 41.3 ± 0.3 | 41.8 ± 0.4 | 41.2 ± 0.6 | 42.4 ± 0.6 | 41.6 ± 0.4 | 41.7 ± 0.3 | 41.0 ± 0.3 | 41.2 ± 0.6 | 41.2 ± 0.3 | 41.4 ± 0.4 | 41.0 ± 0.4 | 41.6 ± 0.7 | |
VMAT RO | 41.1 ± 0.4 | 41.1 ± 0.2 | 41.5 ± 0.4 | 41.0 ± 0.3 | 41.6 ± 0.4 | 41.3 ± 0.3 | 41.2 ± 0.4 | 40.9 ± 0.3 | 40.9 ± 0.3 | 41.0 ± 0.3 | 41.1 ± 0.3 | 40.8 ± 0.4 | 41.4 ± 0.7 |
Isocenter shifted 5 mm | Flash simulation scenario | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROI | Technique | Plan | Medial | Lateral | Posterior | Anterior | Inferior | Superior | SOM1 | SOM2 | SOM3 | SOM4 | SOM5 | CBCT |
Ipsi_Lung | ||||||||||||||
DMean (Gy) | WT | 10.0 ± 1.7 | 10.8 ± 1.8 | 9.1 ± 1.6 | 11.2 ± 1.8 | 8.8 ± 1.6 | 10.8 ± 1.8 | 9.2 ± 1.6 | 9.9 ± 1.7 | 9.8 ± 1.7 | 9.9 ± 1.7 | 9.9 ± 1.7 | 9.9 ± 1.7 | 9.9 ± 1.9 |
VMAT NF | 12.1 ± 0.6 | 13.2 ± 0.7 | 11.1 ± 0.5 | 13.4 ± 0.7 | 11.0 ± 0.5 | 12.8 ± 0.6 | 11.5 ± 0.6 | 12.1 ± 0.6 | 11.9 ± 0.6 | 12.1 ± 0.6 | 12.0 ± 0.6 | 11.9 ± 0.6 | 12.0 ± 0.8 | |
VMAT MF | 12.2 ± 0.6 | 13.0 ± 0.9 | 11.2 ± 0.5 | 13.4 ± 0.7 | 11.3 ± 1.0 | 12.6 ± 0.8 | 11.6 ± 0.8 | 12.1 ± 0.6 | 12.0 ± 0.6 | 12.1 ± 0.6 | 12.0 ± 0.6 | 12.0 ± 0.6 | 12.0 ± 0.6 | |
VMAT RO | 12.6 ± 0.3 | 13.6 ± 0.4 | 11.5 ± 0.2 | 13.8 ± 0.4 | 11.4 ± 0.2 | 13.2 ± 0.3 | 11.9 ± 0.3 | 12.5 ± 0.3 | 12.3 ± 0.3 | 12.5 ± 0.2 | 12.5 ± 0.3 | 12.3 ± 0.3 | 12.4 ± 0.4 | |
V17 Gy (%) | WT | 24.4 ± 5.3 | 26.9 ± 5.6 | 21.7 ± 5.0 | 28.0 ± 5.4 | 21.0 ± 5.2 | 27.0 ± 5.2 | 21.9 ± 4.9 | 24.4 ± 5.3 | 24.3 ± 5.2 | 24.4 ± 5.3 | 24.4 ± 5.3 | 24.3 ± 5.3 | 24.2 ± 5.9 |
VMAT NF | 27.4 ± 2.2 | 30.7 ± 2.5 | 23.9 ± 1.9 | 31.3 ± 2.6 | 23.3 ± 1.8 | 29.4 ± 2.6 | 25.2 ± 2.0 | 27.3 ± 2.2 | 26.9 ± 2.2 | 27.4 ± 2.2 | 27.2 ± 2.2 | 27.0 ± 2.2 | 27.1 ± 2.8 | |
VMAT MF | 27.4 ± 2.2 | 30.8 ± 2.5 | 23.9 ± 2.0 | 31.3 ± 2.6 | 23.3 ± 1.8 | 29.4 ± 1.8 | 25.3 ± 2.0 | 27.4 ± 2.1 | 27.0 ± 2.2 | 27.4 ± 2.2 | 27.2 ± 2.2 | 27.1 ± 2.2 | 27.2 ± 2.8 | |
VMAT RO | 29.0 ± 1.3 | 32.5 ± 1.6 | 25.4 ± 1.3 | 32.9 ± 1.6 | 25.0 ± 1.3 | 31.0 ± 1.8 | 26.9 ± 1.3 | 29.0 ± 1.3 | 28.5 ± 1.4 | 29.0 ± 1.3 | 28.8 ± 1.3 | 28.6 ± 1.4 | 29.0 ± 2.2 | |
Contra_Lung | ||||||||||||||
DMean (Gy) | WT | 0.6 ± 0.0 | 0.7 ± 0.0 | 0.6 ± 0.0 | 0.7 ± 0.0 | 0.6 ± 0.0 | 0.6 ± 0.0 | 0.6 ± 0.0 | 0.6 ± 0.0 | 0.7 ± 0.0 | 0.6 ± 0.0 | 0.6 ± 0.0 | 0.7 ± 0.0 | 0.5 ± 0.0 |
VMAT NF | 1.0 ± 0.2 | 1.1 ± 0.2 | 0.9 ± 0.2 | 1.1 ± 0.2 | 0.9 ± 0.2 | 1.1 ± 0.3 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.1 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.9 ± 0.2 | |
VMAT MF | 1.0 ± 0.2 | 1.1 ± 0.2 | 1.0 ± 0.2 | 1.1 ± 0.2 | 0.9 ± 0.2 | 1.1 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.1 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.1 ± 0.2 | 0.9 ± 0.2 | |
VMAT RO | 1.3 ± 1.0 | 1.5 ± 1.5 | 1.1 ± 0.6 | 1.6 ± 1.5 | 1.1 ± 0.6 | 1.4 ± 1.3 | 1.2 ± 0.7 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.8 ± 0.2 | |
V2.5 Gy (%) | WT | 1.4 ± 0.8 | 1.9 ± 1.0 | 1.1 ± 0.6 | 2.2 ± 1.0 | 0.8 ± 0.5 | 1.6 ± 0.9 | 1.2 ± 0.7 | 1.7 ± 0.9 | 2.0 ± 1.0 | 1.5 ± 0.8 | 1.6 ± 0.8 | 1.9 ± 0.9 | 1.1 ± 0.6 |
VMAT NF | 5.5 ± 4.4 | 6.8 ± 5.1 | 4.4 ± 3.9 | 7.4 ± 4.5 | 4.0 ± 4.3 | 6.4 ± 4.8 | 4.8 ± 4.0 | 5.6 ± 4.3 | 6.2 ± 4.0 | 5.6 ± 4.4 | 5.8 ± 4.3 | 6.1 ± 4.0 | 4.4 ± 3.2 | |
VMAT MF | 5.7 ± 4.3 | 6.9 ± 5.0 | 4.5 ± 3.8 | 7.6 ± 4.4 | 4.5 ± 4.2 | 6.3 ± 4.8 | 5.1 ± 3.9 | 5.8 ± 4.2 | 6.5 ± 3.9 | 5.7 ± 4.2 | 5.9 ± 4.1 | 6.4 ± 3.9 | 4.6 ± 3.1 | |
VMAT RO | 5.1 ± 4.0 | 6.6 ± 4.7 | 3.9 ± 3.4 | 6.9 ± 4.1 | 3.7 ± 3.9 | 5.9 ± 4.4 | 4.4 ± 3.7 | 5.2 ± 3.9 | 5.9 ± 3.7 | 5.2 ± 4.0 | 5.4 ± 3.9 | 5.9 ± 3.7 | 4.1 ± 2.9 | |
Heart | ||||||||||||||
DMean (Gy) | WT | 1.2 ± 0.3 | 1.3 ± 0.3 | 1.1 ± 0.2 | 1.4 ± 0.4 | 1.1 ± 0.2 | 1.3 ± 0.3 | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.3 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.3 ± 0.3 | 1.2 ± 0.3 |
VMAT NF | 2.0 ± 0.7 | 2.2 ± 0.8 | 1.8 ± 0.6 | 2.2 ± 0.8 | 1.8 ± 0.6 | 2.1 ± 0.8 | 1.9 ± 0.6 | 2.0 ± 0.7 | 2.0 ± 0.7 | 2.0 ± 0.7 | 2.0 ± 0.7 | 2.0 ± 0.7 | 2.1 ± 0.8 | |
VMAT MF | 2.0 ± 0.7 | 2.2 ± 0.8 | 1.8 ± 0.6 | 2.2 ± 0.8 | 1.8 ± 0.6 | 2.1 ± 0.8 | 1.9 ± 0.6 | 2.0 ± 0.7 | 2.1 ± 0.7 | 2.0 ± 0.7 | 2.0 ± 0.7 | 2.1 ± 0.7 | 2.1 ± 0.8 | |
VMAT RO | 2.0 ± 0.7 | 2.3 ± 0.8 | 1.8 ± 0.6 | 2.3 ± 0.8 | 1.8 ± 0.6 | 2.1 ± 0.8 | 1.9 ± 0.7 | 2.1 ± 0.7 | 2.1 ± 0.7 | 2.0 ± 0.7 | 2.1 ± 0.7 | 2.1 ± 0.7 | 2.1 ± 0.8 | |
V5 Gy (%) | WT | 0.2 ± 0.6 | 0.4 ± 0.9 | 0.1 ± 0.3 | 0.6 ± 1.2 | 0.0 ± 0.2 | 0.3 ± 0.7 | 0.1 ± 0.4 | 0.2 ± 0.5 | 0.2 ± 0.6 | 0.2 ± 0.5 | 0.2 ± 0.6 | 0.2 ± 0.6 | 0.5 ± 1.0 |
VMAT NF | 4.2 ± 4.7 | 6.3 ± 6.3 | 2.7 ± 3.4 | 5.5 ± 5.8 | 3.2 ± 3.9 | 5.2 ± 5.8 | 3.4 ± 3.9 | 4.2 ± 4.7 | 4.3 ± 4.7 | 4.2 ± 4.8 | 4.3 ± 4.7 | 4.3 ± 4.7 | 5.0 ± 5.2 | |
VMAT MF | 4.3 ± 4.8 | 6.4 ± 6.4 | 2.7 ± 3.4 | 5.7 ± 5.9 | 3.3 ± 3.9 | 5.3 ± 5.8 | 3.5 ± 4.0 | 4.4 ± 4.8 | 4.4 ± 4.8 | 4.4 ± 4.8 | 4.4 ± 4.8 | 4.4 ± 4.9 | 5.1 ± 5.3 | |
VMAT RO | 4.8 ± 5.3 | 7.0 ± 6.8 | 3.1 ± 4.0 | 6.4 ± 6.3 | 3.6 ± 4.6 | 5.7 ± 5.9 | 4.1 ± 5.0 | 4.9 ± 5.4 | 4.9 ± 5.4 | 4.8 ± 5.4 | 4.8 ± 5.3 | 4.9 ± 5.4 | 5.4 ± 5.4 | |
Contra_Breast | ||||||||||||||
DMean (Gy) | WT | 1.6 ± 5.3 | 1.9 ± 1.4 | 1.4 ± 0.9 | 2.1 ± 1.5 | 1.3 ± 0.8 | 1.8 ± 1.2 | 1.5 ± 1.0 | 1.7 ± 1.3 | 2.0 ± 1.5 | 1.7 ± 1.2 | 1.7 ± 1.2 | 2.0 ± 1.5 | 1.6 ± 1.1 |
VMAT NF | 2.1 ± 0.8 | 2.3 ± 1.0 | 1.9 ± 0.7 | 2.5 ± 1.0 | 1.7 ± 0.7 | 2.2 ± 0.9 | 1.9 ± 0.8 | 2.1 ± 0.9 | 2.3 ± 1.1 | 2.1 ± 0.9 | 2.1 ± 0.9 | 2.3 ± 1.1 | 2.0 ± 0.8 | |
VMAT MF | 2.1 ± 2.1 | 2.4 ± 1.0 | 1.9 ± 0.7 | 2.6 ± 1.0 | 1.7 ± 0.7 | 2.3 ± 0.9 | 2.0 ± 0.8 | 2.1 ± 0.9 | 2.4 ± 1.1 | 2.1 ± 0.9 | 2.2 ± 0.9 | 2.4 ± 1.1 | 2.0 ± 0.8 | |
VMAT RO | 2.0 ± 0.8 | 2.3 ± 1.0 | 1.8 ± 0.7 | 2.5 ± 1.1 | 1.6 ± 0.7 | 2.2 ± 0.9 | 1.9 ± 0.8 | 2.0 ± 0.9 | 2.3 ± 1.1 | 2.0 ± 0.9 | 2.1 ± 0.9 | 2.3 ± 1.1 | 1.9 ± 0.8 |
Wide tangent plans

VMAT plans
- •VMAT NF: First a standard VMAT plan was produced as described above without any additional flash margin for the breast (PTVp which was clipped 5 mm from the body contour).
- •VMAT MF: The NF plans MLCs were retracted on all allowable control points where possible to ensure a 2 cm flash margin from the skin. This consisted of firstly creating a flash contour which was 2.5 cm expansion of the PTVp minus the body contour (see appendix). The MLCs positions were manually edited if needed and retracted to the flash contour ensuring a 2 cm margin from the body contour. Only MLC that were not inside the PTVp is where the MLCs were withdrawn back to the flash contour. This ensured that the planned dosimetry to the target was largely unaffected. Further manual optimization of the plan after MLC adjusting was sometimes required to ensure optimal homogeneity in case of new hot spots.
- •VMAT RO: The PTVp was contacted by 5 mm (except anterior and lateral) to create a CTVp. This CTVp was then used as a motion organ to simulate a max motion of 1.5 cm in the anterior and lateral direction to create 3 additional CT datasets (SOM1, 2, and 5) which were used in the plan optimization. This 15 mm margin was based on more recent literature where most extreme swellings were typically within 15 mm and all these patients would be in DIBH.[9],[15],[20],[21]The Ipsi_Lung was kept as a fixed organ for this purpose. This process creates CT datasets and deforms the contours on to them from the planning CT so they can be used during the optimization. This ensures the motion uncertainty is accounted for when creating the control points and fluence. The NF plan was copied and reset in which then the RO plan was then created. This method has been described previously by Dunlop et al.[15]It consists of a minimax optimization where the optimization functions selected (PTV min dose, max dose) are considered in the worst-case scenario. See supplementary data for a detailed procedure.
Robustness evaluations
- 1.SOM CT Scenarios: In addition to the 3 CT scans created in the VMAT RO process, another 2 were created which were intermediate amounts of the max 1.5 cm tissue deformations. The WT and VMAT plans were then recomputed on these 5 CT scans (SOM 1 to 5) and the resultant dose statistics were recorded. A CTVp_SP structure was also created which consisted of the most superficial 1 cm to capture the impact of the superficial component of the CTVp. This resulted in a total of 200 dose calculations (4 techniques × 5 CT scenarios × 10 patients). The 5 SOM scenarios consisted of deformation of the CTVp by various amounts (cm) per direction: SOM1: (1.5 cm lateral), SOM2: (1.5 cm anterior), SOM3: (0.75 cm lateral), SOM4: (0.75 cm anterior), SOM5: (0.79 cm lateral and 1.28 cm anterior).
- 2.CBCT calculations: WT patients had daily CBCT imaging with online image matching. The CBCT scans were imported into Raystation and fused in the treatment position to the planning CT for every fraction of each plan. To calculate daily doses, additional CBCT structures were created such as a field of view (FOV), body, body minus FOV, and Ipsi_Lung (given density 1.0 g/cc), Ipsi_Lung minus FOV inside the body (given density of 0.26 g/cc). Where CBCT data were missing inferiorly due to scan lengths not capturing some inferior components of the PTVp, missing body contours were created and given a density of 1 g/cc. Each fractional dose was then computed on the CBCT using the auto image value to density table (IVDT) in Raystation and deformed back to the planning CT for summation. Estimated total delivered doses could then be assessed. This resulted in a total of 600 dose calculations (4 techniques × 15 fractions × 10 patients).
- 3.Isocenter Shifts: Each plans isocenter was shifted by 5 mm in the anterior, posterior, medial, lateral, superior, and inferior direction and recalculated to assess dosimetric impact on CTV coverage and OAR doses. This resulted in a total of 240 dose calculations (4 techniques × 6 shift scenarios × 10 patients).
Statistical analysis
Results
WT and VMAT plan doses
CTV dose
- 1SOM 5 CT Scenarios: Fig. 2 shows for CTVp V38Gy, the NF plans were the least robust with RO plans the most becoming more superior as anatomical changes increased. WT and MF plans showed generally similar levels of robustness. The nodal CTVs V36Gy did not change significantly with anatomical for VMAT plans (< 2%) but WT demonstrated slightly larger reductions being mostly within 5%. The CTVp V42.8Gy changes was relatively stable and low for VMAT RO and NF plans and tended to be higher with anatomical changes for VMAT MF.Fig. 2Mean CTV dose differences for the 4 techniques (WT, VMAT NF, VMAT MF, and VMAT RO) for isocenter shifts and anatomical changes. (Color version of figure is available online.)Fig. 3Mean OAR dose differences for the 4 techniques (WT, VMAT NF, VMAT MF, and VMAT RO) for isocenter shifts and anatomical changes. (Color version of figure is available online.)
- 2
- 3Isocenter shifts (5 mm): The CTVp V38Gy reduced by a max of 8.4% (NF postshift). All other directions and plans had small changes for CTVp (< 5%). For the CTVn_IMN, VMAT plans showed little changes for coverage (within 2%). WT CTVn_IMN V36Gy, however, reduced by an average of 7.6%, 12.8%, and 8.1% for shift directions lateral, anterior, and superior, respectively. For CTVn_LN only the anterior and superior isocenter shift tended to give reduced nodal V36Gy but within 3% for WT. Max dose increases to CTVp were more likely for MF plans with a mean max absolute increase in D0.5cc of 0.5Gy (SOM2, -0.65 - 2.2 Gy). RO VMAT plans appeared to be most stable with the smallest changes for both D0.5cc and V42.8Gy (Fig. 2).
OAR dose
- 1
- 2CBCT calculations: Changes were minimal (typically < 0.3 Gy mean dose or < 1% change in volume receiving a dose). There were no obvious differences between techniques.
- 3Isocenter Shifts (5 mm): Larger dosimetric changes were seen for isocentric shifts than for anatomical changes but still remained on average within 1.5 Gy OAR mean dose. The OAR dose increased for all techniques for medial, posterior, and inferior isocenter shifts. Comparing techniques showed little difference across plans except for Heart V5Gy which tended to be less sensitive to change for the WT plans.
Discussion
Conclusion
Authors Contribution
Conflicts of interest
Acknowledgments
Appendix. Supplementary materials
References
World Health Organisation, 2021, Available at: https://www.who.int/news-room/fact-sheets/detail/cancer . Accessed November 2021.
Cancer Research UK, Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero. Accessed November 2021.
- Postoperative radiotherapy for breast cancer: UK consensus statements.Clinical Oncol. November 2016; (Available at:) (Accessed November 2021)
- Implementation of Royal College of Radiologists Consensus Statements and National Institute for Health and Care Excellence Guidance: breast radiotherapy practice in the UK.Clin. Oncol. 2021; 33: 419-426https://doi.org/10.1016/j.clon.2021.01.012
- Selection criteria for early breast cancer patients in the DBCG proton trial—The randomised phase III trial strategy.Clin. Transl. Radiat. Oncol. 2021; 27: 126-131https://doi.org/10.1016/j.ctro.2021.01.012
- A dosimetric comparison of breast radiotherapy techniques to treat locoregional lymph nodes including the internal mammary chain.Clin. Oncol. 2018; 30: 346-353https://doi.org/10.1016/j.clon.2018.01.017
- Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer.Radiat. Oncol. 2017; 12: 200https://doi.org/10.1186/s13014-017-0935-4
- Tangential volumetric modulated arc therapy technique for left-sided breast cancer radiotherapy.Radiat. Oncol. 2015; 10: 79https://doi.org/10.1186/s13014-015-0392-x
- Breast deformation during the course of radiotherapy: The need for an additional outer margin.Physica. Medica. 2019; 65: 1-5https://doi.org/10.1016/j.ejmp.2019.07.021
- Safety and benefit of using a virtual bolus during treatment planning for breast cancer treated with arc therapy.J. Appl. Clin. Med. Phys. 2018; 19: 463-472https://doi.org/10.1002/acm2.12398
- Planning strategies in volumetric modulated arc therapy for breast.Med. Phys. 2011; 38: 4025-4031https://doi.org/10.1118/1.3598442
- The effect of optimization on surface dose in intensity modulated radiotherapy (IMRT).Phys. Med. Biol. 2004; 49: 4919-4928https://doi.org/10.1088/0031-9155/49/21/005
- Virtual bolus for inversion radiotherapy planning in intensity-modulated radiotherapy of breast carcinoma within the scope of adjuvant therapy.Strahlenther. Onkol. 2002; 178: 139-146https://doi.org/10.1007/s00066-002-0915-x
- Robustness of VMAT and 3DCRT plans toward setup errors in radiation therapy of locally advanced left-sided breast cancer with DIBH.Physica. Medica. 2018; 45: 12-18https://doi.org/10.1016/j.ejmp.2017.11.019
- Evaluation of organ motion-based robust optimization for VMAT planning for breast and internal mammary chain radiotherapy.Clin. Transl. Radiat. Oncol. 2019; 16: 60-66https://doi.org/10.1016/j.ctro.2019.04.004
- A robust volumetric arc therapy planning approach for breast cancer involving the axillary nodes.Medical Dosimetry. 2019; 44: 183-189https://doi.org/10.1016/j.meddos.2018.06.001
National Institute for Health Research NIHR funding and awards search website (2020). Available at: https://fundingawards.nihr.ac.uk/award/NIHR131120. Accessed March, 2022
- ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.Radiother. Oncol. 2015; 114: 3-10https://doi.org/10.1016/j.radonc.2014.11.030
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.Lancet. 2020; 395: 1613-1626https://doi.org/10.1016/S0140-6736(20)30932-6
- Inter-fraction motion and dosimetric consequences during breast intensity-modulated radiotherapy (IMRT).Radiother. Oncol. 2009; 90: 93-98https://doi.org/10.1016/j.radonc.2008.10.010
- Inter- and intra-fraction motion during radiation therapy to the whole breast in the supine position: a systematic re-view.J. Med. Imaging Radiat. Oncol. 2021; 56: 499-509https://doi.org/10.1111/j.1754-9485.2012.02434.x
- Can underdosage due to breast swelling be mitigated with robust optimization for breast radiotherapy.Radiother. Oncol. 2020; 152: S1039-S1040https://doi.org/10.1016/S0167-8140(21)01882-X
- Using robust optimization for skin flashing in intensity modulated radiation therapy for breast cancer treatment: A feasibility study.Pract. Radiat. Oncol. 2020; 10: 59-69https://doi.org/10.1016/j.prro.2019.09.017
- Comparison of CT number calibration techniques for CBCT-based dose calculation.Strahlenther. Onkol. 2015; 191: 970-978https://doi.org/10.1007/s00066-015-0890-7
- In regards to Bogue J, Wan J, Lavey RS, Parsai EI. Dosimetric comparison of VMAT with integrated skin flash to 3D field-in-field tangents for left breast irradiation.J. Appl. Clin. Med. Phys. 2019; 20: 24-29https://doi.org/10.1002/acm2.12607